06877 CLSA PREMIUM
- 0.070
- 0.0000.00%
CLSA PREMIUM News
CLSA PREMIUM (06877) profit before tax for the first quarter was approximately HK$1.8 million, up more than 150% year over year
According to the Zhitong Finance App, CLSA PREMIUM (06877) issued an announcement. According to the Group's unaudited comprehensive management accounts for the 3 months ended March 31, 2024, unaudited revenue exceeded HK$20 million, mainly from product sales through the company's B2B and B2C distribution channels. For the three months ended March 31, 2024, unaudited profit before tax was approximately HK$1.8 million, an increase of more than 150% compared with the unaudited profit before tax of HK$700,000 for the three months ended March 31, 2023. Furthermore, compared to the first quarter of 2023
CLSA PREMIUM: 2023 ANNUAL REPORT
CLSA PREMIUM announces annual results, annual profit of HK$9.842 million, and turns year-on-year loss into profit
CLSA PREMIUM (06877) announced audited results for the year ended 31 December 2023. Total revenue from continuing operations was approximately HK$200 million, up 410.37% year on year; annual profit from continuing operations of HK$12.83 million, which turned a year-on-year loss into profit; annual profit of HK$9.842 million, while a loss of HK$31.05 million was recorded in the same period in 2022; and profit of HK$0.48 per share. According to reports, the increase in net profit was mainly due to significant growth in the health care business in 2023, and the revenue from sales of health products exceeded 3 times that of 2022.
CLSA PREMIUM (06877) announced annual results, with an annual profit of HK$9.842 million, turning a year-on-year loss into a profit
CLSA PREMIUM (06877) released Audited for the year ended December 31, 2023...
CLSA PREMIUM: AUDITED RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
Ministry of Finance: The total profit of state-owned enterprises in 2023 was 4633.28 billion yuan, up 7.4% year-on-year
From January to December, the main efficiency indicators of state-owned and state-owned enterprises across the country continued to grow steadily, and the upward trend was further consolidated.
CLSA Premium to Return to Profit
CLSA Premium (HKG:6877) expects a consolidated net profit of almost HK$7.7 million for the year through December 2023, as against a loss of about HK$31.1 million in the preceding year. The forex trade
CLSA PREMIUM (06877) is expected to achieve annual net profit of approximately HK$7.7 million, turning a year-on-year loss into profit
According to Zhitong Finance App, CLSA PREMIUM (06877) issued an announcement. The board of directors of the company expects the Group to obtain a consolidated net profit of about HK$7.7 million for the year ended 31 December 2023, and an audited net loss of about HK$31.1 million for the year ended 31 December 2022. The expected net profit is mainly due to a significant increase in the healthcare business in 2023, and the revenue from sales of health products more than tripled the 2022 revenue. Furthermore, trading continues to be suspended.
CLSA PREMIUM: POSITIVE PROFIT ALERT AND QUARTERLY UPDATE ON PROGRESS OF RESUMPTION
CLSA PREMIUM: 2023 Interim Report
CLSA Premium Swings to Profit in H1
CLSA Premium (HKG:6877) recorded a profit attributable to shareholders of HK$5.6 million for the first half, swinging from the loss of HK$17.5 million a year earlier. Earnings per share stood at HK$0.
CLSA PREMIUM announces first-half results, net profit of HK$5.554 million, turning a year-on-year loss into a profit
CLSA PREMIUM (06877) announced results for the first half of 2023. Total revenue from continuing operations was about HK$143 million, an increase of about 15.74 times; net profit of HK$5.554 million, net loss of HK$17.495,000 for the same period last year; and profit of HK$0.27 cents per share.
CLSA PREMIUM: UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023
CLSA PREMIUM (06877.HK) will hold a board meeting on August 14 to approve interim results
On July 28, 丨CLSA PREMIUM (06877.HK) announced that a board meeting will be held on August 14, 2023 to approve the company and its subsidiaries' interim results and announcements for the six months ended June 30, 2023, and consider the payment of interim dividends (if any).
CLSA PREMIUM: NOTIFICATION OF BOARD MEETING
CLSA Premium Expects Return to Profit in First Half
CLSA Premium (HKG:6877) expects to swing to a net profit of HK$5.2 million in the six months ended June 30 from a loss of HK$17.5 million a year earlier, a Monday filing said. The swing to profitabili
CLSA PREMIUM Fa Yingxi expects a net profit of HK$5.2 million in the medium term
CLSA PREMIUM (06877) announced that the board of directors expects the Group to obtain an unaudited net profit of about HK$5.2 million, while an unaudited comprehensive net loss of around HK$17.5 million in the same period in 2022. Expected net profit is mainly a combination of the following factors: the growth of the health products business in the first half of 2023 and the Group's continued actions to streamline operations and improve business efficiency. Expenses were reduced in the first half of 2023 compared to the first half of 2022, including staff costs of approximately HK$7.6 million and IT maintenance and support expenses of about HK$1.2 million.
CLSA PREMIUM: POSITIVE PROFIT ALERT AND QUARTERLY UPDATE ON PROGRESS OF RESUMPTION
Hong Kong Bourse Upholds Suspension on CLSA Premium's Shares; Shares Tumble 12%
11:33 PM EDT, 04/13/2023 (MT Newswires) -- The listing committee of the Hong Kong Stock Exchange resolved to uphold its decision to suspend CLSA Premium's (HKG:6877) shares. The suspension comes after
CLSA PREMIUM: 2022 Annual Report
Analysis
Price Target
No Data
